WuXi Biologics Reports Record 2025 Annual Results
Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) EBITDA rose 38.1% YoY and...